Literature DB >> 25361778

Motoric cognitive risk syndrome: Multicenter incidence study.

Joe Verghese1, Emmeline Ayers2, Nir Barzilai2, David A Bennett2, Aron S Buchman2, Roee Holtzer2, Mindy J Katz2, Richard B Lipton2, Cuiling Wang2.   

Abstract

OBJECTIVE: To report incidence and risk factors for motoric cognitive risk syndrome (MCR), a newly described predementia syndrome characterized by slow gait and cognitive complaints.
METHODS: We examined incidence rates of MCR in 3,128 adults aged 60 years and older, MCR- and dementia-free at baseline, participating in 4 US-based cohort studies. Hazard ratios (HRs) with 95% confidence intervals (CIs) for the association of modifiable risk factors with risk of MCR were computed using Cox models.
RESULTS: Over a median follow-up time of 3.2 years, 823 of the 3,128 participants met MCR criteria. The overall age- and sex-adjusted incidence of MCR was 65.2/1,000 person-years (95% CI: 53.3-77.1), and ranged from 50.8/1,000 person-years to 79.6/1,000 person-years in the individual cohorts. MCR incidence was higher with older age but there were no sex differences. In the pooled sample adjusted for age, sex, education, and cohort source, strokes (HR 1.42, 95% CI: 1.14-1.77), Parkinson disease (HR 2.52, 95% CI: 1.68-3.76), depressive symptoms (HR 1.65, 95% CI: 1.28-2.13), sedentariness (HR 1.76, 95% CI: 1.44-2.17), and obesity (HR 1.39, 95% CI: 1.17-1.65) predicted risk of incident MCR.
CONCLUSIONS: The incidence of MCR is high in older adults. Identification of modifiable risk factors for MCR will improve identification of high-risk individuals and help develop interventions to prevent cognitive decline in aging.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Year:  2014        PMID: 25361778      PMCID: PMC4277675          DOI: 10.1212/WNL.0000000000001084

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  Mild cognitive impairment, incidence, progression, and reversion: findings from a community-based cohort of elderly African Americans.

Authors:  Sujuan Gao; Frederick W Unverzagt; Kathleen S Hall; Kathleen A Lane; Jill R Murrell; Ann M Hake; Valerie Smith-Gamble; Hugh C Hendrie
Journal:  Am J Geriatr Psychiatry       Date:  2013-07-03       Impact factor: 4.105

Review 3.  Cognitive and social lifestyle: links with neuropathology and cognition in late life.

Authors:  David A Bennett; Steven E Arnold; Michael J Valenzuela; Carol Brayne; Julie A Schneider
Journal:  Acta Neuropathol       Date:  2013-12-20       Impact factor: 17.088

4.  Alzheimer's disease: a correlational analysis of the Blessed Information-Memory-Concentration Test and the Mini-Mental State Exam.

Authors:  L J Thal; M Grundman; R Golden
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

5.  Abnormality of gait as a predictor of non-Alzheimer's dementia.

Authors:  Joe Verghese; Richard B Lipton; Charles B Hall; Gail Kuslansky; Mindy J Katz; Herman Buschke
Journal:  N Engl J Med       Date:  2002-11-28       Impact factor: 91.245

6.  Assessing mobility difficulties for cross-national comparisons: results from the World Health Organization Study on Global AGEing and Adult Health.

Authors:  Benjamin D Capistrant; M Maria Glymour; Lisa F Berkman
Journal:  J Am Geriatr Soc       Date:  2014-01-17       Impact factor: 5.562

7.  Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the Mayo Clinic Study of Aging.

Authors:  Michelle M Mielke; Rosebud O Roberts; Rodolfo Savica; Ruth Cha; Dina I Drubach; Teresa Christianson; Vernon S Pankratz; Yonas E Geda; Mary M Machulda; Robert J Ivnik; David S Knopman; Bradley F Boeve; Walter A Rocca; Ronald C Petersen
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-12-18       Impact factor: 6.053

8.  Unique lipoprotein phenotype and genotype associated with exceptional longevity.

Authors:  Nir Barzilai; Gil Atzmon; Clyde Schechter; Ernst J Schaefer; Adrienne L Cupples; Richard Lipton; Suzanne Cheng; Alan R Shuldiner
Journal:  JAMA       Date:  2003-10-15       Impact factor: 56.272

9.  Motoric cognitive risk syndrome: multicountry prevalence and dementia risk.

Authors:  Joe Verghese; Cedric Annweiler; Emmeline Ayers; Nir Barzilai; Olivier Beauchet; David A Bennett; Stephanie A Bridenbaugh; Aron S Buchman; Michele L Callisaya; Richard Camicioli; Benjamin Capistrant; Somnath Chatterji; Anne-Marie De Cock; Luigi Ferrucci; Nir Giladi; Jack M Guralnik; Jeffrey M Hausdorff; Roee Holtzer; Ki Woong Kim; Paul Kowal; Reto W Kressig; Jae-Young Lim; Susan Lord; Kenichi Meguro; Manuel Montero-Odasso; Susan W Muir-Hunter; Mohan L Noone; Lynn Rochester; Velandai Srikanth; Cuiling Wang
Journal:  Neurology       Date:  2014-07-16       Impact factor: 9.910

10.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Tony Dans; Alvaro Avezum; Fernando Lanas; Matthew McQueen; Andrzej Budaj; Prem Pais; John Varigos; Liu Lisheng
Journal:  Lancet       Date:  2004 Sep 11-17       Impact factor: 79.321

View more
  55 in total

1.  Cerebral Small Vessel Disease and Motoric Cognitive Risk Syndrome: Results from the Kerala-Einstein Study.

Authors:  Nan Wang; Gilles Allali; Chandrasekharan Kesavadas; Mohan L Noone; Vayyattu G Pradeep; Helena M Blumen; Joe Verghese
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

2.  Symptoms of Apathy Independently Predict Incident Frailty and Disability in Community-Dwelling Older Adults.

Authors:  Emmeline Ayers; Miriam Shapiro; Roee Holtzer; Nir Barzilai; Sofiya Milman; Joe Verghese
Journal:  J Clin Psychiatry       Date:  2017-05       Impact factor: 4.384

3.  Spatial navigation and risk of cognitive impairment: A prospective cohort study.

Authors:  Joe Verghese; Richard Lipton; Emmeline Ayers
Journal:  Alzheimers Dement       Date:  2017-03-03       Impact factor: 21.566

4.  Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults.

Authors:  Neelesh K Nadkarni; Oscar L Lopez; Subashan Perera; Stephanie A Studenski; Beth E Snitz; Kirk I Erickson; Chester A Mathis; Robert D Nebes; Mark Redfern; William E Klunk
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-03-01       Impact factor: 6.053

5.  The association of anxio-depressive disorders and depression with motoric cognitive risk syndrome: results from the baseline assessment of the Canadian longitudinal study on aging.

Authors:  Harmehr Sekhon; Gilles Allali; Olivier Beauchet
Journal:  Geroscience       Date:  2019-08-28       Impact factor: 7.713

Review 6.  A Narrative Review of Handgrip Strength and Cognitive Functioning: Bringing a New Characteristic to Muscle Memory.

Authors:  Keith A Shaughnessy; Kyle J Hackney; Brian C Clark; William J Kraemer; Donna J Terbizan; Ryan R Bailey; Ryan McGrath
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

7.  Association of anti-inflammatory cytokine IL10 polymorphisms with motoric cognitive risk syndrome in an Ashkenazi Jewish population.

Authors:  Sanish Sathyan; Nir Barzilai; Gil Atzmon; Sofiya Milman; Emmeline Ayers; Joe Verghese
Journal:  Neurobiol Aging       Date:  2017-06-19       Impact factor: 4.673

8.  Non-memory subjective cognitive concerns predict incident motoric cognitive risk syndrome.

Authors:  C Nester; E Ayers; L Rabin; J Verghese
Journal:  Eur J Neurol       Date:  2020-05-19       Impact factor: 6.089

9.  Motoric Cognitive Risk Syndrome in Polypharmacy.

Authors:  Claudene J George; Joe Verghese
Journal:  J Am Geriatr Soc       Date:  2020-02-24       Impact factor: 5.562

10.  Motoric Cognitive Risk Syndrome and Falls Risk: A Multi-Center Study.

Authors:  Michele L Callisaya; Emmeline Ayers; Nir Barzilai; Luigi Ferrucci; Jack M Guralnik; Richard B Lipton; Petr Otahal; Velandai K Srikanth; Joe Verghese
Journal:  J Alzheimers Dis       Date:  2016-06-18       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.